Helio Vision

Helio Vision was founded in 2016 to develop a therapy for rare, fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The co-founders of Helio Vision, Massachusetts Eye and Ear Infirmary physicians Drs. Dean Eliott and Tomasz Stryjewski, have discovered that by using sustained intravitreal exposure to methotrexate, a medication with anti-proliferative and anti-inflammatory properties, this dreaded post-operative scarring cycle may be prevented. ​